BioCentury | Jun 29, 2015
Finance

Pulmatrix's breathing room

...like an expedited route, as there was a fully listed shell with some cash" in Ruthigen Inc....
BioCentury | Jun 22, 2015
Company News

Pulmatrix, Ruthigen deal

...completed its reverse merger with Ruthigen (see BioCentury, April 13). Pulmatrix Inc. (NASDAQ:PULM), Lexington, Mass. Ruthigen Inc....
BioCentury | Jun 22, 2015
Financial News

Pulmatrix completes debt financing

...raised $10 million in a venture offering prior to completing its reverse merger with Ruthigen Inc. Ruthigen...
BioCentury | Jun 17, 2015
Financial News

Pulmatrix finds public path via Ruthigen merger

...to $11.80 in its first day of trading after it completed a reverse merger with Ruthigen Inc....
BioCentury | Apr 13, 2015
Company News

Pulmatrix, Ruthigen deal

...Pulmatrix will reverse-merge with Ruthigen, with Pulmatrix shareholders owning 81% of the surviving entity. The newco...
...the close of the merger, which is expected this quarter. Pulmatrix Inc. , Lexington, Mass. Ruthigen Inc....
BioCentury | Nov 3, 2014
Clinical News

RUT58-60: Phase I/II started

...lavages with RUT58-60 or saline and 1 lavage with RUT58-60 or saline above the fascia. Ruthigen...
...quarter and of 130 patients in the Phase II portion by the end of 1Q15. Ruthigen Inc....
BioCentury | Jul 28, 2014
Clinical News

RUT58-60: Phase I started

...to start a 28-day, double-blind Phase I/II trial in 150 patients following an IDMC review. Ruthigen Inc....
BioCentury | May 12, 2014
Financial News

Ruthigen financial update

...to $20.3 million. The company, which closed Friday at $6.30, has 4.8 million shares outstanding. Ruthigen Inc....
BioCentury | Apr 7, 2014
Finance

2Q14 Financial Markets Preview: Minor adjustment

...3/26/14 $57.5 $168.2 $210.3 25% Horizon Discovery Group plc (LSE:HZD) 3/24/14 $66.0 $198.7 $227.5 14% Ruthigen Inc....
BioCentury | Apr 7, 2014
Company News

Oculus, Ruthigen dermatology news

...that it made modifications to its corporate governance following the IPO of its former subsidiary, Ruthigen...
...of Ruthigen common stock, or about a 43% stake, based on shares outstanding immediately after Ruthigen's...
...management. Microcyn is a solution containing oxychlorine compounds. Oculus Innovative Sciences Inc. (NASDAQ:OCLS), Petaluma, Calif. Ruthigen Inc....
Items per page:
1 - 10 of 32
BioCentury | Jun 29, 2015
Finance

Pulmatrix's breathing room

...like an expedited route, as there was a fully listed shell with some cash" in Ruthigen Inc....
BioCentury | Jun 22, 2015
Company News

Pulmatrix, Ruthigen deal

...completed its reverse merger with Ruthigen (see BioCentury, April 13). Pulmatrix Inc. (NASDAQ:PULM), Lexington, Mass. Ruthigen Inc....
BioCentury | Jun 22, 2015
Financial News

Pulmatrix completes debt financing

...raised $10 million in a venture offering prior to completing its reverse merger with Ruthigen Inc. Ruthigen...
BioCentury | Jun 17, 2015
Financial News

Pulmatrix finds public path via Ruthigen merger

...to $11.80 in its first day of trading after it completed a reverse merger with Ruthigen Inc....
BioCentury | Apr 13, 2015
Company News

Pulmatrix, Ruthigen deal

...Pulmatrix will reverse-merge with Ruthigen, with Pulmatrix shareholders owning 81% of the surviving entity. The newco...
...the close of the merger, which is expected this quarter. Pulmatrix Inc. , Lexington, Mass. Ruthigen Inc....
BioCentury | Nov 3, 2014
Clinical News

RUT58-60: Phase I/II started

...lavages with RUT58-60 or saline and 1 lavage with RUT58-60 or saline above the fascia. Ruthigen...
...quarter and of 130 patients in the Phase II portion by the end of 1Q15. Ruthigen Inc....
BioCentury | Jul 28, 2014
Clinical News

RUT58-60: Phase I started

...to start a 28-day, double-blind Phase I/II trial in 150 patients following an IDMC review. Ruthigen Inc....
BioCentury | May 12, 2014
Financial News

Ruthigen financial update

...to $20.3 million. The company, which closed Friday at $6.30, has 4.8 million shares outstanding. Ruthigen Inc....
BioCentury | Apr 7, 2014
Finance

2Q14 Financial Markets Preview: Minor adjustment

...3/26/14 $57.5 $168.2 $210.3 25% Horizon Discovery Group plc (LSE:HZD) 3/24/14 $66.0 $198.7 $227.5 14% Ruthigen Inc....
BioCentury | Apr 7, 2014
Company News

Oculus, Ruthigen dermatology news

...that it made modifications to its corporate governance following the IPO of its former subsidiary, Ruthigen...
...of Ruthigen common stock, or about a 43% stake, based on shares outstanding immediately after Ruthigen's...
...management. Microcyn is a solution containing oxychlorine compounds. Oculus Innovative Sciences Inc. (NASDAQ:OCLS), Petaluma, Calif. Ruthigen Inc....
Items per page:
1 - 10 of 32